Leading Russian pharmaceutical company Genetics Pharmaceuticals / Zavod Medsintez LLC, a major insulin manufacturer, will invest approximately $80 million in Pakistan’s pharmaceutical sector over the next six years. The investment marks a significant boost for local manufacturing of essential diabetes medications.
Read More: Habib Metropolitan Bank Reappoints Khurram Shahzad Khan as CEO and Mohamedali R. Habib as Chairman
The Drug Regulatory Authority of Pakistan (DRAP) has conditionally fixed the Maximum Retail Price (MRP) for six insulin products of the Russian company while directing the company to immediately begin construction of local manufacturing plants, with full completion required by December 2031.
Investment Breakdown
| Stage | Investment | Purpose | Completion Deadline |
|---|---|---|---|
| Stage 1 | $20 million | Aseptic filling plant (bulk import + aseptic filling of insulin) | December 31, 2028 |
| Stage 2 | $60 million | API production plant (biotechnological insulin production from API to finished form) | December 31, 2031 |
| Total | $80 million | – | – |
Regulatory Framework
The DRAP notification states: “In exercise of the powers conferred by clause (a) of section 7 of the Drug Regulatory Authority of Pakistan Act, 2012 (XXI of 2012) read with section 12 of the Drugs Act, 1976 (XXXI of 1976), the DRAP with the approval of the federal government is pleased to fix maximum retail prices specified in the table below, subject to the specified conditions.”
Conditions for Price Approval
The maximum retail prices (MRPs) have been granted subject to the following conditions:
- Immediate commencement of manufacturing facility construction
- Stage 1 completion (aseptic filling plant) by December 31, 2028
- Stage 2 completion (API production plant) by December 31, 2031
- Timeline sharing – The company shall share stage-wise detailed timelines for investment
- Progress monitoring – DRAP shall monitor progress
- Compliance requirement – In case of non-compliance, product registration shall be cancelled
Approved Insulin Products
The DRAP has approved MRP for the following Russian insulin product:
| Product | Details |
|---|---|
| Product Name | Rosinsulin C 100IU/ml, Insulin Isophane (N) |
| Form | 10 ml suspension for subcutaneous administration |
| Manufacturer | Zavod Medsintez (Zavod Medsintez, LLC), Russia |
| Importer | M/s Genetics Pharmaceuticals (Pvt) Ltd, Lahore |
Strategic Significance
This investment represents a major step toward reducing Pakistan’s reliance on imported insulin and other biologic medicines. Local manufacturing of insulin will enhance supply chain security, potentially lower costs for patients, and strengthen Pakistan’s pharmaceutical manufacturing capabilities for complex biologic products.
About Genetics Pharmaceuticals / Zavod Medsintez LLC
Genetics Pharmaceuticals / Zavod Medsintez LLC is a leading Russian pharmaceutical company specializing in the production of insulin and other biotechnological products. The company has established itself as a key player in the global diabetes care market.
About DRAP
The Drug Regulatory Authority of Pakistan (DRAP) is the federal regulatory body responsible ensuring the safety, efficacy, and quality of drugs, biologics, and medical devices in Pakistan.
